Shannon Schrader
Assistant Professor of PsychiatryAbout
Research
Publications
2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
Aberg J, Shepherd B, Wang M, Madruga J, Mendo Urbina F, Katlama C, Schrader S, Eron J, Kumar P, Sprinz E, Gartland M, Chabria S, Clark A, Pierce A, Lataillade M, Tenorio A. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1. Infectious Diseases And Therapy 2023, 12: 2321-2335. PMID: 37751019, PMCID: PMC10581994, DOI: 10.1007/s40121-023-00870-6.Peer-Reviewed Original ResearchTreatment-experienced adultsCells/mm3Virologic responseWeek 96Week 240Background therapyAdverse eventsDrug-related serious adverse eventsMultidrug-resistant human immunodeficiency virusCurrent antiretroviral regimenNon-randomized cohortOptimized background therapySerious adverse eventsT-cell countsHuman immunodeficiency virusKey therapeutic optionNew safety concernsCoronavirus disease 2019Antiretroviral regimenImmunologic efficacyRandomized cohortCurrent regimenImmunodeficiency virusImmunologic responseTherapeutic optionsPotentially Traumatic Events of Women of Color in an Urban Adult Basic Education Program
Crouch M, Miller-Roenigk B, Schrader S, Griffith F, Simmons S, Gordon D. Potentially Traumatic Events of Women of Color in an Urban Adult Basic Education Program. Journal Of Aggression Maltreatment & Trauma 2023, 33: 432-450. PMID: 38798799, PMCID: PMC11114608, DOI: 10.1080/10926771.2023.2231384.Peer-Reviewed Original ResearchAdult Basic EducationTraumatic eventsLife Events ChecklistAdult basic education programsGeneralized anxiety disorderPaucity of researchEvents ChecklistTrauma typesABE studentsAnxiety disordersHigh school graduationMillions of studentsAnxiety scoresWomen of colorBasic education programsPresent researchHigher ratingsSchool graduationHealth QuestionnaireEducational needsPatient Health QuestionnaireStudentsDiverse peopleMore researchDepression
2018
Pilot study of a brief dialectical behavior therapy skills group for jail inmates.
Moore KE, Folk JB, Boren EA, Tangney JP, Fischer S, Schrader SW. Pilot study of a brief dialectical behavior therapy skills group for jail inmates. Psychol Serv 2018, 15: 98-108. PMID: 27617479, DOI: 10.1037/ser0000105.Peer-Reviewed Original Research
2017
Is There a Dark Side to Mindfulness? Relation of Mindfulness to Criminogenic Cognitions.
Tangney JP, Dobbins AE, Stuewig JB, Schrader SW. Is There a Dark Side to Mindfulness? Relation of Mindfulness to Criminogenic Cognitions. Pers Soc Psychol Bull 2017, 43: 1415-1426. PMID: 28918714, DOI: 10.1177/0146167217717243.Peer-Reviewed Original ResearchDoes psychopathy differentially predict treatment-seeking during incarceration versus postrelease?
Schrader SW, Tangney JP, Stuewig JB. Does psychopathy differentially predict treatment-seeking during incarceration versus postrelease? J Offender Rehabil 2017, 57: 207-221. PMID: 31105413, DOI: 10.1080/10509674.2017.1400487.Peer-Reviewed Original Research
2007
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
Nadler J, Berger D, Blick G, Cimoch P, Cohen C, Greenberg R, Hicks C, Hoetelmans R, Iveson K, Jayaweera D, Mills A, Peeters M, Ruane P, Shalit P, Schrader S, Smith S, Steinhart C, Thompson M, Vingerhoets J, Voorspoels E, Ward D, Woodfall B. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007, 21: f1-f10. PMID: 17413684, DOI: 10.1097/qad.0b013e32805e8776.Peer-Reviewed Original ResearchConceptsNon-nucleoside reverse transcriptase inhibitorsPrimary protease inhibitorHIV-1 RNAHIV-1Antiretroviral agentsNNRTI-resistant HIV-1HIV-1 RNA levelsIntention-to-treat populationSafety of etravirineHepatic adverse eventsControl groupResistant HIV-1Reverse transcriptase inhibitorsDose-related effectsRandomized clinical trialsEtravirine groupPI resistanceOpen-labelPrimary endpointViral loadSafety profileTranscriptase inhibitorsControl patientsAdverse eventsGenotypic resistance
2005
Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency
Lori F, Pollard R, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J. Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency. AIDS Research And Human Retroviruses 2005, 21: 263-272. PMID: 15943568, DOI: 10.1089/aid.2005.21.263.Peer-Reviewed Original ResearchConceptsCD4+ cell countHIV-infected patientsCell countLong-term managementHigher CD4+ cell countsPlasma HIV-1 RNA levelsChronically HIV-infected patientsCD8+ cell countsHIV-1 RNA levelsIntent-to-treat populationCD4+/CD8+ cell ratioAssociated with fewer adverse eventsEnd pointsEfficacy of hydroxyureaEfficacy end pointWeeks of therapyOpen-label studyPrimary end pointProportion of patientsFewer adverse eventsDose of hydroxyureaAntiretroviral drugsHIV/AIDS worldwideEfficacy parametersDaily dose
2004
Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV
Squires K, Lazzarin A, Gatell J, Powderly W, Pokrovskiy V, Delfraissy J, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 36: 1011-1019. PMID: 15247553, DOI: 10.1097/00126334-200408150-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkynesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveAtazanavir SulfateBenzoxazinesCD4 Lymphocyte CountCyclopropanesDouble-Blind MethodDrug Administration ScheduleFemaleHIV InfectionsHumansLamivudineMaleMiddle AgedOligopeptidesOxazinesPyridinesRNA, ViralZidovudineConceptsHIV RNA levelsAntiretroviral therapy regimenHIV RNA levels <Median CD4 cell countProportion of treated patientsAzapeptide protease inhibitorComparator-treated patientsOnce-daily atazanavirRNA levelsCD4 cell countTreatment-naive patientsEfficacy end pointLow-density lipoprotein cholesterolOnce-daily dosingWeeks of therapyProtease inhibitorsDouble-dummyBilirubin elevationTreatment discontinuationDouble-blindAtazanavir treatmentActive-controlledFasting triglyceridesTreated patientsFasting GlucoseOnce-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial
DeJesus E, McCarty D, Farthing C, Shortino D, Grinsztejn B, Thomas D, Schrader S, Castillo S, Sension M, Gough K, Madison S, Team E. Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial. Clinical Infectious Diseases 2004, 39: 411-418. PMID: 15307010, DOI: 10.1086/422143.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkynesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCD4 Lymphocyte CountCyclopropanesDisease ProgressionDouble-Blind MethodDrug Administration ScheduleDrug Resistance, ViralFemaleHIV InfectionsHIV-1HumansLamivudineMaleMiddle AgedOxazinesReverse Transcriptase InhibitorsRNA, ViralViral LoadZidovudineConceptsOnce-DailyTwice-dailyHuman immunodeficiency virus-infected adultsCD4(+) cell countHIV-1 RNA levelsIncidence of adverse eventsAntiretroviral-naive adultsHIV-associated conditionsRegimen of lamivudineRandomized equivalence trialProportion of patientsIntent-to-treat analysisConfidence intervalsDouble-dummyDouble-blindHIV infectionTreatment failureMulticenter trialAdverse eventsHIV-1Disease progressionMedian increaseCell countRNA levelsEquivalence trialCD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies
Arduino R, Nannini E, Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende M, Emery S, Fosdick L, Neaton J, Tavel J, Davey R, Lane H, Committee E. CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies. Clinical Infectious Diseases 2004, 39: 115-122. PMID: 15206062, DOI: 10.1086/421775.Peer-Reviewed Original ResearchConceptsCD4 cell countCD4 cell count changeSubcutaneous interleukin-2Human immunodeficiency virusDose groupControl regimenCell countInterleukin-2CD4 cell count increaseHIV-1-infected subjectsResponse to 3 dosesBaseline CD4 cell countCount changesClinical end point trialsCD4 cell responseCycles of therapyCell count increaseMeta-analysisControl groupTreatment of patientsEnd-point trialsContemporaneous control groupAntiretroviral therapyImmunodeficiency virusMonth 6
Get In Touch
Contacts
Mailing Address
Psychiatry
950 Campbell Avenue
West Haven, CT 06516
United States